Company Overview - Xencor is a biotechnology company founded on advanced protein engineering technology, recognized for creating antibodies with best-in-class properties [2] - The company has developed multiple marketed products and its technology is widely utilized in the pharmaceutical industry, contributing to a broad pipeline in oncology and autoimmune diseases [2] Pipeline Focus - Xencor is currently concentrating on building its proprietary pipeline of drugs, particularly focusing on solid tumors and T-cell engagers, a rapidly emerging class in cancer treatment [3] - The company aims to define the dosing regimens and efficacy safety profiles for its two lead solid tumor T-cell engager CD3 bispecific antibodies, XmAb819 and XmAb541, with expectations to establish recommended Phase III doses and pivotal plans within the next 12 to 18 months [3]